Separate naringin and naringenin mouse findings from limited human research, and check what product claims leave unproven.
Naringin and naringenin have interesting experimental hair-growth findings, but neither is established as a treatment for androgenetic alopecia. Mouse results do not establish an effective human scalp concentration, an oral dose or a safe combination with minoxidil.
They are related compounds, not interchangeable names. Naringin is a glycoside of naringenin. Evidence for one preparation cannot be transferred automatically to the other, or from a topical mouse experiment to an oral supplement.
The Zheng and colleagues paper, published online in January 2026, compared naringin preparations, saline and minoxidil in C57BL/6J mice. The accessible primary abstract reports hair-regrowth and tissue measurements, with the strongest naringin response at the highest tested concentration. It also reports changes in Wnt/β-catenin-associated markers and VEGF-A.
These findings support further research. A mouse comparison with minoxidil does not demonstrate equal or superior treatment of human pattern hair loss. The study also does not establish that changing a molecular marker is enough to restore hair in patients. We reviewed the primary abstract; the full publisher article was not accessible for checking all methodological details.
A separate 2023 paper studied 24 mice, divided into four groups of six. Researchers compared a vehicle, naringenin, minoxidil and their combination over 21 days after clipping dorsal hair. They measured regrowth, follicle features and tissue markers.
The authors reported improved growth measures with the combination. This was not a clinical add-on trial in people already using minoxidil. Clipped mouse back hair does not reproduce the full course of longstanding human androgenetic alopecia, and three weeks cannot establish long-term human safety.
The experiment therefore does not justify mixing a powder into a commercial minoxidil bottle. Its animal formulation is not a validated patient prescription.
It would be inaccurate to say naringenin has never been studied in people. A 2019 paper on alopecia areata combined cell experiments with a brief account of 20 people using a naringenin-containing gel for three months. The human section does not report a randomized control group or adequate numerical clinical outcomes. Alopecia areata is also a different condition from androgenetic alopecia. The paper cannot establish treatment efficacy for pattern hair loss.
An oral pharmacokinetic trial in 18 healthy adults studied single doses, blood concentrations and short-term safety measurements. It did not test hair regrowth. Such a study cannot establish that a long-term hair supplement or a topical mixture is effective and safe.
Our September 21, 2026 search did not identify a controlled human androgenetic-alopecia trial that resolves these gaps. This is a dated search finding, not a guarantee that every unpublished or unindexed study has been located.
Before treating a “Wnt activator” claim as evidence of benefit, check:
An ingredient being found in citrus does not answer those questions. Grapefruit products can also interact with medicines; the FDA's interaction guidance recommends checking the specific drug and product. That warning does not mean every purified flavonoid has the same interaction profile.
For now, these studies do not support a do-it-yourself scalp mixture, application after microneedling or a promised response window. Bring a proposed product's full ingredients to your clinician or pharmacist. Our human-evidence checklist and hair-loss add-on review can help you evaluate the claim before changing treatment.
Powered by BTST